Latest Lynx1 Capital Management LP Stock Portfolio
$632Million– No. of Holdings #23
Lynx1 Capital Management LP Performance:
2026 Q1: 12.51%YTD: 12.51%2025: 63.54%
Performance for 2026 Q1 is 12.51%, and YTD is 12.51%, and 2025 is 63.54%.
About Lynx1 Capital Management LP and 13F Hedge Fund Stock Holdings
Lynx1 Capital Management LP is a hedge fund based in San Juan, PR. On 2026-05-04, the fund reported it's updated stock portfolio. In the 13F Holdings report, Lynx1 Capital Management LP reported an equity portfolio of $632.7 Millions as of 31 Mar, 2026.
The top stock holdings of Lynx1 Capital Management LP are STOK, GHRS, CGEM. The fund has invested 24.5% of it's portfolio in STOKE THERAPEUTICS INC and 23.9% of portfolio in GH RESEARCH PLC.
The fund managers got completely rid off ARROWHEAD PHARMACEUTICALS IN (ARWR), MAPLIGHT THERAPEUTICS INC and GENERATION BIO CO (GBIO) stocks. They significantly reduced their stock positions in IMMATICS N.V (IMTX), XENCOR INC (XNCR) and STOKE THERAPEUTICS INC (STOK). Lynx1 Capital Management LP opened new stock positions in VYNE THERAPEUTICS INC (VYNE), IBIO INC (IBIO) and BOLT BIOTHERAPEUTICS INC (BOLT). The fund showed a lot of confidence in some stocks as they added substantially to AGIOS PHARMACEUTICALS INC (AGIO), ENTRADA THERAPEUTICS INC (TRDA) and KORRO BIO INC.
The top stock holdings of Lynx1 Capital Management LP are STOK, GHRS, CGEM. The fund has invested 24.5% of it's portfolio in STOKE THERAPEUTICS INC and 23.9% of portfolio in GH RESEARCH PLC.
The fund managers got completely rid off ARROWHEAD PHARMACEUTICALS IN (ARWR), MAPLIGHT THERAPEUTICS INC and GENERATION BIO CO (GBIO) stocks. They significantly reduced their stock positions in IMMATICS N.V (IMTX), XENCOR INC (XNCR) and STOKE THERAPEUTICS INC (STOK). Lynx1 Capital Management LP opened new stock positions in VYNE THERAPEUTICS INC (VYNE), IBIO INC (IBIO) and BOLT BIOTHERAPEUTICS INC (BOLT). The fund showed a lot of confidence in some stocks as they added substantially to AGIOS PHARMACEUTICALS INC (AGIO), ENTRADA THERAPEUTICS INC (TRDA) and KORRO BIO INC.
Lynx1 Capital Management LP Equity Portfolio Value
Last Reported on: 04 May, 2026
Lynx1 Capital Management LP Annual Return Estimates Vs S&P 500
Our best estimate is that Lynx1 Capital Management LP made a return of 12.51% in the last quarter. In trailing 12 months, it's portfolio return was 112.11%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| vyne therapeutics inc | 973,148 |
| ibio inc | 129,344 |
| bolt biotherapeutics inc | 124,432 |
| absci corporation | 63,735 |
| traws pharma inc | 27,593 |
New stocks bought by Lynx1 Capital Management LP
Additions
| Ticker | % Inc. |
|---|---|
| agios pharmaceuticals inc | 3,179 |
| entrada therapeutics inc | 309 |
| korro bio inc | 126 |
| design therapeutics inc | 71.93 |
| denali therapeutics inc | 8.14 |
| gh research plc | 3.43 |
| werewolf therapeutics inc | 0.28 |
| neuphoria therapeutics inc | 0.01 |
Additions to existing portfolio by Lynx1 Capital Management LP
Reductions
| Ticker | % Reduced |
|---|---|
| immatics n.v | -76.47 |
| xencor inc | -23.98 |
| stoke therapeutics inc | -11.86 |
| c4 therapeutics inc | -1.4 |
| precision biosciences inc | -0.89 |
Lynx1 Capital Management LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| applied therapeutics inc | -41,050 |
| generation bio co | -142,000 |
| maplight therapeutics inc | -236,724 |
| arrowhead pharmaceuticals in | -799,535 |
Lynx1 Capital Management LP got rid off the above stocks
Sector Distribution
Lynx1 Capital Management LP has about 72.1% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 72.1 |
| Others | 27.9 |
Market Cap. Distribution
Lynx1 Capital Management LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
- SMALL-CAP
- UNALLOCATED
- MID-CAP
- MICRO-CAP
| Category | % |
|---|---|
| SMALL-CAP | 60.3 |
| UNALLOCATED | 27.9 |
| MID-CAP | 5.7 |
| MICRO-CAP | 5.1 |
Stocks belong to which Index?
About 66% of the stocks held by Lynx1 Capital Management LP either belong to S&P 500 or RUSSELL 2000 index.
- RUSSELL 2000
- Others
| Index | % |
|---|---|
| RUSSELL 2000 | 66 |
| Others | 34 |
Lynx1 Capital Management LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Lynx1 Capital Management LP
Lynx1 Capital Management LP has 23 stocks in it's portfolio. About 97.1% of the portfolio is in top 10 stocks. PASG proved to be the most loss making stock for the portfolio. CGEM was the most profitable stock for Lynx1 Capital Management LP last quarter.
Last Reported on: 04 May, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABSI | absci corporation | 0.01 | 21,245 | 63,735 | new | |||
| AGIO | agios pharmaceuticals inc | 13.96 | 2,611,570 | 88,349,300 | added | 3,179 | ||
| APLT | applied therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ARWR | arrowhead pharmaceuticals in | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BOLT | bolt biotherapeutics inc | 0.02 | 30,800 | 124,432 | new | |||
| CCCC | c4 therapeutics inc | 2.91 | 6,998,900 | 18,407,100 | reduced | -1.4 | ||
| CGEM | cullinan therapeutics inc | 20.13 | 8,963,500 | 127,371,000 | unchanged | 0.00 | ||
| DNLI | denali therapeutics inc | 5.71 | 1,880,300 | 36,101,800 | added | 8.14 | ||
| DSGN | design therapeutics inc | 0.20 | 119,516 | 1,271,650 | added | 71.93 | ||
| DTIL | precision biosciences inc | 0.86 | 985,113 | 5,418,120 | reduced | -0.89 | ||
| GBIO | generation bio co | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| GHRS | gh research plc | 23.92 | 10,763,300 | 151,332,000 | added | 3.43 | ||
| HOWL | werewolf therapeutics inc | 0.09 | 657,786 | 547,673 | added | 0.28 | ||
| IBIO | ibio inc | 0.02 | 68,076 | 129,344 | new | |||
| IMTX | immatics n.v | 0.34 | 216,973 | 2,135,010 | reduced | -76.47 | ||
| ONTX | traws pharma inc | 0.00 | 15,078 | 27,593 | new | |||
| PASG | passage bio inc | 0.77 | 623,704 | 4,896,080 | unchanged | 0.00 | ||
| PRQR | proqr thrapeutics n v | 0.02 | 68,486 | 110,947 | unchanged | 0.00 | ||
| STOK | stoke therapeutics inc | 24.51 | 4,763,670 | 155,105,000 | reduced | -11.86 | ||
| TCRX | tscan therapeutics inc | 1.28 | 8,019,150 | 8,099,340 | unchanged | 0.00 | ||